Inavolisib-Based Therapy for PIK3CA-Mutated Advanced Male Breast Cancer: A Cost-Effectiveness Analysis
Xiaoting Huang, Shen Lin, Rongfang Lin, Shaohong Luo, Pinfang Huang, Dayong Zeng · 2025
Read Inavolisib-Based Therapy for PIK3CA-Mutated Advanced Male Breast Cancer: A Cost-Effectiveness Analysis by Xiaoting Huang, Shen Lin, Rongfang Lin, Shaohong Luo, Pinfang Huang, Dayong Zeng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12753842.txt.
Description
Xiaoting Huang and co-authors priced a new breast cancer drug plan in 2025 for men with advanced disease. Breast cancer in men is rare and often left out of trials. The drug plan adds a targeted pill to two standard drugs for cancers with a set gene change. A large trial in women showed the plan works better as a first line. The team built a lifetime cost model from a United States payer's view.
The plan added more than a year of life and about two thirds of a year of good-quality life. Its cost per good year came near nine hundred thousand dollars, far above the usual pay cap. The pill's price drove that gap. No chance showed in their tests that the plan pays off at the cap.
Catalog record
| CREATOR | Xiaoting Huang, Shen Lin, Rongfang Lin, Shaohong Luo, Pinfang Huang, Dayong Zeng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |